vs
Eightco Holdings Inc.（ORBS）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Eightco Holdings Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.1倍（$10.2M vs $9.1M），Protalix BioTherapeutics, Inc.净利率更高（-60.3% vs -2281.6%，领先2221.3%），Eightco Holdings Inc.同比增速更快（-49.9% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-11.0M），过去两年Eightco Holdings Inc.的营收复合增速更高（13.1% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
ORBS vs PLX — 直观对比
营收规模更大
ORBS
是对方的1.1倍
$9.1M
营收增速更快
ORBS
高出0.1%
-49.9%
净利率更高
PLX
高出2221.3%
-2281.6%
自由现金流更多
PLX
多$12.6M
$-11.0M
两年增速更快
ORBS
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $10.2M | $9.1M |
| 净利润 | $-232.5M | $-5.5M |
| 毛利率 | -13.0% | 49.4% |
| 营业利润率 | -475.0% | -51.1% |
| 净利率 | -2281.6% | -60.3% |
| 营收同比 | -49.9% | -49.9% |
| 净利润同比 | -9183.3% | -184.8% |
| 每股收益（稀释后） | $-2.34 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ORBSPLX
| Q4 25 | $10.2M | $9.1M | ||
| Q3 25 | $5.3M | $17.9M | ||
| Q2 25 | $7.6M | $15.7M | ||
| Q1 25 | $9.9M | $10.1M | ||
| Q4 24 | $20.3M | $18.2M | ||
| Q3 24 | $6.1M | $18.0M | ||
| Q2 24 | $5.3M | $13.5M | ||
| Q1 24 | $8.0M | — |
净利润ORBSPLX
| Q4 25 | $-232.5M | $-5.5M | ||
| Q3 25 | $-25.8M | $2.4M | ||
| Q2 25 | $-1.2M | $164.0K | ||
| Q1 25 | $-2.5M | $-3.6M | ||
| Q4 24 | $-2.5M | $6.5M | ||
| Q3 24 | $-3.2M | $3.2M | ||
| Q2 24 | $4.4M | $-2.2M | ||
| Q1 24 | $1.9M | — |
毛利率ORBSPLX
| Q4 25 | -13.0% | 49.4% | ||
| Q3 25 | -3.7% | 53.4% | ||
| Q2 25 | 16.4% | 62.5% | ||
| Q1 25 | 8.2% | 19.1% | ||
| Q4 24 | 8.2% | 78.7% | ||
| Q3 24 | 26.5% | 53.4% | ||
| Q2 24 | 25.1% | 29.8% | ||
| Q1 24 | 17.5% | — |
营业利润率ORBSPLX
| Q4 25 | -475.0% | -51.1% | ||
| Q3 25 | -116.9% | 11.9% | ||
| Q2 25 | -15.9% | 7.5% | ||
| Q1 25 | -14.3% | -41.0% | ||
| Q4 24 | -11.9% | 39.6% | ||
| Q3 24 | -29.1% | 22.2% | ||
| Q2 24 | -16.4% | -18.0% | ||
| Q1 24 | -39.6% | — |
净利率ORBSPLX
| Q4 25 | -2281.6% | -60.3% | ||
| Q3 25 | -487.6% | 13.2% | ||
| Q2 25 | -15.4% | 1.0% | ||
| Q1 25 | -25.7% | -35.8% | ||
| Q4 24 | -12.3% | 35.6% | ||
| Q3 24 | -52.5% | 18.0% | ||
| Q2 24 | 84.2% | -16.4% | ||
| Q1 24 | 24.4% | — |
每股收益（稀释后）ORBSPLX
| Q4 25 | $-2.34 | $-0.06 | ||
| Q3 25 | $-0.58 | $0.03 | ||
| Q2 25 | $-0.38 | $0.00 | ||
| Q1 25 | $-0.84 | $-0.05 | ||
| Q4 24 | $-1.44 | $0.10 | ||
| Q3 24 | $-1.77 | $0.03 | ||
| Q2 24 | $2.15 | $-0.03 | ||
| Q1 24 | $1.42 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $58.5M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $232.6M | $48.2M |
| 总资产 | $250.2M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ORBSPLX
| Q4 25 | $58.5M | $14.7M | ||
| Q3 25 | $23.7M | $13.6M | ||
| Q2 25 | $696.3K | $17.9M | ||
| Q1 25 | $434.4K | $19.5M | ||
| Q4 24 | $239.2K | $19.8M | ||
| Q3 24 | $2.4M | $27.4M | ||
| Q2 24 | $363.1K | $23.4M | ||
| Q1 24 | $808.8K | — |
股东权益ORBSPLX
| Q4 25 | $232.6M | $48.2M | ||
| Q3 25 | $339.2M | $52.9M | ||
| Q2 25 | $8.9M | $49.9M | ||
| Q1 25 | $9.7M | $45.2M | ||
| Q4 24 | $11.9M | $43.2M | ||
| Q3 24 | $13.0M | $32.4M | ||
| Q2 24 | $13.8M | $28.6M | ||
| Q1 24 | $3.9M | — |
总资产ORBSPLX
| Q4 25 | $250.2M | $82.3M | ||
| Q3 25 | $355.5M | $82.3M | ||
| Q2 25 | $48.7M | $78.5M | ||
| Q1 25 | $47.6M | $73.9M | ||
| Q4 24 | $50.8M | $73.4M | ||
| Q3 24 | $49.2M | $61.6M | ||
| Q2 24 | $48.4M | $91.5M | ||
| Q1 24 | $50.2M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.0M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $-11.0M | $1.6M |
| 自由现金流率自由现金流/营收 | -107.7% | 17.8% |
| 资本支出强度资本支出/营收 | 0.0% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流ORBSPLX
| Q4 25 | $-11.0M | $2.0M | ||
| Q3 25 | $-1.6M | $-3.7M | ||
| Q2 25 | $-659.2K | $-5.2M | ||
| Q1 25 | $999.8K | $-5.1M | ||
| Q4 24 | $-6.6M | $4.0M | ||
| Q3 24 | $77.7K | $4.1M | ||
| Q2 24 | $-440.3K | $-3.6M | ||
| Q1 24 | $-723.3K | — |
自由现金流ORBSPLX
| Q4 25 | $-11.0M | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | $-661.3K | $-5.7M | ||
| Q1 25 | $999.7K | $-5.4M | ||
| Q4 24 | $-6.6M | $3.6M | ||
| Q3 24 | $73.0K | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率ORBSPLX
| Q4 25 | -107.7% | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | -8.7% | -36.2% | ||
| Q1 25 | 10.1% | -53.0% | ||
| Q4 24 | -32.7% | 19.6% | ||
| Q3 24 | 1.2% | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
资本支出强度ORBSPLX
| Q4 25 | 0.0% | 4.4% | ||
| Q3 25 | 0.0% | 2.8% | ||
| Q2 25 | 0.0% | 2.8% | ||
| Q1 25 | 0.0% | 3.0% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
现金转化率ORBSPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | -0.10× | — | ||
| Q1 24 | -0.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ORBS
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
